ClinicalTrials.gg
CompletedNCT03427333Updated Mar 29, 2019

Rook Epicardial Access Device Study

An interventional study of The Rook® Epicardial Access Kit in Ventricular Tachycardia and Arrythmia, sponsored by Talon Surgical. Completed at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-29.

Sponsored by Talon Surgical · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was Jun 2018, 8 years 3 months ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to confirm the efficacy and safety of the Talon Surgical Rook® Epicardial Access Kit as a pericardial access device. The Rook® Epicardial Access Kit will be used to gain access the epicardial surface of the heart via a subxiphoid approach in adult patients with a normal, non-distended pericardial space.

Read the detailed description

This is a first-in-human, prospective, non-randomized, single arm study to confirm the efficacy and safety of the Talon Surgical Rook® Epicardial Access Kit to achieve guidewire access to the pericardial space. Patients who are clinically indicated to undergo a procedure that requires percutaneous access to the normal, non-distended, pericardial space will be considered for enrollment into this clinical trial. This may include, but is not limited to, patients who require pericardial access for epicardial ablation procedure or for pigtail catheter placement during pacemaker lead extraction. The study population will consist of both male and female patients of at least 18 years of age. In addition, eligible patients will have a life expectancy of at least 6 months based on a physician's assessment of the patient's medical condition. Patients who meet all inclusion and non-exclusion criteria, who are willing to comply with study follow-up requirements, and for whom documented informed consent is obtained, will be eligible for enrollment in the study. Enrollment occurs when the device enters the body.

Patients who undergo attempted use of a study device (patient leaves procedure room with device having entered the body at some point during the procedure), regardless of whether or not the device was successfully used for pericardial access, will be followed through discharge or up to 4 days post procedure, whichever comes first.

The study will include a minimum of 10 patients and up to 30 patients with the study devices used for pericardial access. Multiple study site may be utilized. The duration of participation for each enrolled patient who utilizes a study device for pericardial access will be through hospital discharge, or up to 4 days post procedure, whichever comes first.

A study physician will utilize the Rook® Epicardial Access Kit to gain access to the pericardial space. The physician will follow the patient through hospital discharge, or up to 4 days post procedure, whichever comes first, for adverse events, and other device or procedure related observations. The study coordinator or designated study personnel at the Principle Investigator's office will be responsible for collecting data from the procedure and hospital stay which will be necessary for completion of case report form for the index procedure and subsequent follow up.

02

Conditions studied

  • Ventricular Tachycardia
  • Arrythmia

Keywords

  • VT
  • Pacemaker Lead Extraction
  • epicardial access
  • pericardial access
03

In context

Tachycardia, Ventricular

443 studies on the registry are indexed under Tachycardia, Ventricular; 120 are open to participants now.

This study's enrollment of 13 is below the median of 64 across 269 interventional studies indexed under Tachycardia, Ventricular.

Browse Tachycardia, Ventricular studies →

Lead sponsor

This is the only study on the registry with Talon Surgical as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is clinically indicated to undergo a procedure that requires percutaneous access to the normal, non-distended, pericardial space.
  • Patient is willing and able to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Subject is younger than 18 years of age
  • Previous cardiac surgery
  • Myocardial infarction within 4 weeks prior to procedure
  • Class IV NYHA (New York Heart Association) heart failure symptoms
  • Subject with an active systemic infection
  • Known carotid artery stenosis greater than 80%
  • Presence of thrombus in the left atrium
  • Congenital absence of a pericardium
  • Coagulopathy
  • Hemodynamic Instability
  • Acute conditions (i.e. electrolyte abnormality, acute ischemia, drug toxicity)
  • Severe hepatic dysfunction or enlargement
  • Subject has Body Mass Index > 40
  • Life expectancy less than 6 months
  • Subject is pregnant
  • Subject is currently participating in another investigational drug or device study that clinically interferes with the endpoints of this study
  • Subject has known or suspected allergy to contrast media
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    The Rook® Epicardial Access Kit

    The Rook® Epicardial Access Kit will be used to gain access the epicardial surface of the heart via a subxiphoid approach in adult patients with a normal, non-distended pericardial space.

    Device: The Rook® Epicardial Access Kit

Interventions

  • DeviceThe Rook® Epicardial Access Kit

    Use of the Rook Epicardial Access Kit to gain access to the normal, non distended pericardial space.

06

What researchers measure

Primary outcomes

  1. Percentage of Patient in Whom Successful Pericardial Access was Achieved Through Use of the Rook Epicardial Access Kit

    Standard x-ray (fluoroscopy) will be used to confirm that the Talon Surgical Rook® Epicardial Access Kit facilitated successful placement of a guidewireinto the pericardial space. Successful placement of the guidewire into the pericardial space will be noted for each patient. The percentage of patients in whom pericardial access was successful will be reported.

    Time frame: At time of intervention.

Secondary outcomes

  1. Number of Participants with Device or Procedure Related Adverse Events as Adjudicated by the Clinical Event Committee

    Occurrence of CEC-adjudicated device or procedure related adverse events through hospital discharge or up to 4 days post procedure, whichever comes first, will be documented for each patient. The total number of patients with adverse events and the number of each adverse events will be reported. This outcome will also be reported as a percentage.

    Time frame: Up to 4 days post procedure.

  2. Speed of Access

    Time from skin incision to confirmed guidewire access to the pericardial space.

    Time frame: At time of intervention

  3. Ease of Use

    Evaluation of the study procedure compared to the standard of care pericardial access procedure with a Tuohy Needle by clinician survey.

    Time frame: At time of intervention.

07

Study locations

1 site
  • Na Homolce Hospital
    Prague, Czechia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03427333
Lead sponsor
Talon Surgical
Responsible party
Sponsor
First posted
Feb 9, 2018
Start date
Jan 18, 2018
Primary completion
Jun 30, 2018
Completion
Feb 25, 2019
Last update
Mar 29, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion